FOLH1 and metastatic neoplasm: With the advancement in imaging and availability of 68Ga prostate‐specific membrane antigen (PSMA) PET, there are higher rates of early detection of micro‐metastatic disease and improved patient selection for MDT compared with conventional imaging.20